Jessica L. Davis

Indiana University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Year:

2026

Aims Rhabdomyosarcoma (RMS) is rare, but it is the most common sarcoma in childhood. The World Health Organisation classifies RMS into four main categories, sharing the same terminology of RMS, but the subtypes have different morphology, clinical behaviour and underlying molecular characterisation. Although the main diagnostic categories have remained the same there have been changes in the histological criteria, together with integration of both immunohistochemical and molecular data in the reporting of RMS. Integrated histology reporting provides valuable information for the management of children with RMS, is important for patients enrolled into clinical trials, supports tissue‐based biological research and contributes to data required in cancer registries. Consistent, comprehensive and reproducible reporting of RMS is imperative. Methods and results In this article we provide the International Collaboration on Cancer Reporting (ICCR) process for the development of the first international Paediatric RMS data set for the reporting of biopsy and resection specimens. An international expert panel consisting of pathologists and paediatric oncologists produced a set of core and non‐core elements to be included in the histopathology reporting of paediatric RMS, inclusive of clinical, macroscopic, microscopic and ancillary testing required for a comprehensive report. The selection of data items was based on review of current evidence, taking into account items that are recognised as essential for patient treatment stratification and that are currently in use in the clinical trial setting. Commentary was provided for each data item to detail the rationale for selecting it as core or non‐core element, and to highlight their clinical relevance. Conclusions The first international data set for the reporting of paediatric RMS aims to promote standardised, high‐quality reporting and supports uniform data collection, which is critical for clinical data comparison on a global level, ultimately improving patient outcome.

Year:

2025

Year:

2025

Year:

2025

Purpose: Doxorubicin is the first-line treatment for metastatic soft-tissue sarcomas. Ribociclib, a cyclin-dependent kinase 4/6 intargets the retinoblastoma pathway to induce cell-cycle arrest at the G 1 –S cell-cycle checkpoint. We hypothesized that administering ribociclib prior to doxorubicin to synchronize cell-cycle progression among tumor cells may enhance the efficacy of doxorubicin. Patients and Methods: Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment before administration of doxorubicin. The primary objective was to establish the recommended phase II dose of the sequenced drug combination. Secondary objectives included progression-free survival and objective response rate. Exploratory correlative studies assessed pharmacokinetic and pharmacodynamic measures. Results: Of 38 screened patients, 16 were enrolled and 15 were evaluable for dose determination. The most common reason for exclusion was lack of normal retinoblastoma protein expression. At dose level 0 (ribociclib 400 mg and doxorubicin 75 mg/m 2 ), four of seven patients experienced febrile neutropenia as a dose-limiting toxicity. Of the eight patients treated at dose level −1 (ribociclib 400 mg and doxorubicin 60 mg/m 2 ), one had a dose-limiting toxicity of grade 4 anemia. Three patients achieved partial response (objective response rate, 20.0%). Ribociclib pharmacokinetic levels were lower than predicted. Levels of phosphorylated retinoblastoma protein in on-treatment tumor biopsy tissue were variable and did not correlate with ribociclib plasma levels. Conclusions: The recommended phase II dose is ribociclib 400 mg followed by doxorubicin 60 mg/m 2 , which demonstrated an acceptable toxicity profile.

Year:

2025

Year:

2023

Collaborators (17)

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Raya Saab

Stanford University

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Ajay Gupta

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Lara Davis

Fred Hutch Cancer Center

UNITED STATES
View details

Kelly M. Bailey

Associate Professor, Director AYA Translational Oncology

Mayo Clinic

UNITED STATES
View details

Miguel Reyes-Mugica

Clinical Professor of Pathology. Division Director of Pediatric and Developmental Pathology

University of Miami Miller School of Medicine

UNITED STATES
View details

Emile Latour

Oregon Health & Science University

UNITED STATES
View details

Sapna Oberoi

Associate Professor

University of Manitoba

CANADA
View details

Sarah Dry

David Geffen School of Medicine at UCLA

UNITED STATES
View details

David Douglass

Associate Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

Sintawat Wangsiricharoen

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Susan M. Hiniker

Stanford University

UNITED STATES
View details

Michael Michal

-

CZECH REPUBLIC
View details

Go Nishikawa

University of Minnesota Twin Cities

UNITED STATES
View details

Skye C. Mayo

-

UNITED STATES
View details

Monika Davare

Oregon Health & Science University

UNITED STATES
View details